Abbott Laboratories

$ABT ABBOTTS beats on earnings but we expect pullback

152
Abbotts quite simply does not miss earnings, a fantastic company and fantastic product in the ever increasing market of Diabetes treatment. Despite this we see a little stagnant price action lately and a pullback is quite possible.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。